Mankind Pharma enters into in-licensing agreement with Betta Pharmaceuticals for Ensartinib

Strategic agreement to strengthen Mankind Pharma’s oncology portfolio with a US FDA-approved targeted therapy for ALK-positive non-small cell lung cancer

Mankind Pharma, one of India’s leading pharmaceutical companies, has entered into an in-licensing agreement with Betta Pharmaceuticals for Ensartinib, a novel, patented oncology drug approved by the US Food and Drug Administration (US FDA) and China’s National Medical Products Administration (NMPA). The drug is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.

Under the terms of the license agreement, Mankind Pharma will pay Betta Pharmaceuticals an upfront payment, potential development and sales milestone payments, and royalty payments on the annual net sales of Ensartinib in India. Mankind Pharma will be granted an exclusive license to develop, manufacture, register, and commercialize Ensartinib in India, subject to the terms and conditions of the license agreement.

The agreement marks another step in Mankind Pharma’s efforts to strengthen its oncology portfolio through strategic collaborations with global pharmaceutical innovators and expand its presence in specialised therapies.

Ensartinib is a targeted therapy designed to inhibit ALK, a protein that can drive cancer growth in a subset of patients with NSCLC. ALK-positive lung cancer represents a distinct molecular subtype of the disease, for which targeted therapies play an important role in treatment.

This move aligns with Mankind Pharma’s broader strategy of expanding its portfolio through a combination of in-house capabilities and external partnerships, with a focus on innovative therapies addressing significant unmet medical needs.

Atish Majumdar, Senior President, Mankind Pharma, said:  “Our ambition is to build a differentiated oncology portfolio that brings innovative therapies to the forefront of our growth strategy. The in-licensing of Ensartinib marks a significant step in this journey, strengthening our focus on specialised therapies and reinforcing our commitment to strategic partnerships that complement our capabilities. We see this as an opportunity to accelerate our presence in oncology, expand our therapeutic capabilities and build a stronger foundation for bringing advanced treatment options to patients in India.”

Together, Mankind Pharma’s pharmaceutical capabilities and Betta Pharmaceuticals’ expertise in oncology innovation, reflect a shared commitment to advancing targeted treatment options and addressing evolving patient needs.

Shizhe Ding, Chairman Assistant and Head of Business Development, Betta Pharmaceuticals said: “Ensartinib represents an important advancement in targeted therapy for patients with ALK-positive non-small cell lung cancer. Our partnership with Mankind Pharma brings together complementary strengths and a shared commitment to expanding therapeutic options towards a more global patient base. We see this collaboration as an opportunity to extend the reach of Ensartinib and to expand upon its clinical potential. We hope this collaboration indicates a strong start of actualizing the fruition of oncology research into meaningful progress for patients around the world.”

The introduction of Ensartinib in India will be subject to applicable regulatory approvals and the completion of relevant commercial and operational requirements. Further details on the agreement will be announced in due course.

Betta PharmaceuticalsEnsartinibin-licensing agreementMankind Pharma
Comments (0)
Add Comment